Evidence map›Paper›PMID 36845728›Full record

ArticleFrontiers in oncology2023

CD203c is expressed by human fetal hepatoblasts and distinguishes subsets of hepatoblastoma.

Marcus O Muench, Marina E Fomin, Alan G Gutierrez, Dolores López-Terrada, Renata Gilfanova, Christopher Nosworthy, Ashley I Beyer, Gregory Ostolaza, Dina Kats, Kevin L Matlock and 2 more

Abstract read
In one paragraph

Article in Frontiers in oncology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
  4. Maternal Western Diet Programmes Bile Acid Dysregulation and Hepatic Fibrosis in Fetal and Juvenile Macaques.Liver international : official journal of the International Association for the Study of the Liver · 2025
    Article
  5. Impact of theFrontiers in endocrinology · 2025
    Article
  6. Insights into the mechanisms of angiogenesis in hepatoblastoma.Frontiers in cell and developmental biology · 2025
    Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Marcus O MuenchVitalant Research Institute, San Francisco, CA, United States.
Marina E FominVitalant Research Institute, San Francisco, CA, United States.
Alan G GutierrezVitalant Research Institute, San Francisco, CA, United States.
Dolores López-TerradaDepartment of Pathology and Immunology, Baylor College of Medicine, Houston, TX, United States.
Renata GilfanovaVitalant Research Institute, San Francisco, CA, United States.
Christopher NosworthyVitalant Research Institute, San Francisco, CA, United States.
Ashley I BeyerVitalant Research Institute, San Francisco, CA, United States.
Gregory OstolazaVitalant Research Institute, San Francisco, CA, United States.
Dina KatsPediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.
Kevin L MatlockOmics Data Automation, Beaverton, OR, United States.
Stefano CairoResearch and Development Unit, XenTech, Evry, France.
Charles KellerPediatric Cancer Biology, Children's Cancer Therapy Development Institute, Beaverton, OR, United States.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background & Aims: Hepatocytic cells found during prenatal development have unique features compared to their adult counterparts, and are believed to be the precursors of pediatric hepatoblastoma. The cell-surface phenotype of hepatoblasts and hepatoblastoma cell lines was evaluated to discover new markers of these cells and gain insight into the development of hepatocytic cells and the phenotypes and origins of hepatoblastoma. Methods: Human midgestation livers and four pediatric hepatoblastoma cell lines were screened using flow cytometry. Expression of over 300 antigens was evaluated on hepatoblasts defined by their expression of CD326 (EpCAM) and CD14. Also analyzed were hematopoietic cells, expressing CD45, and liver sinusoidal-endothelial cells (LSECs), expressing CD14 but lacking CD45 expression. Select antigens were further examined by fluorescence immunomicroscopy of fetal liver sections. Antigen expression was also confirmed on cultured cells by both methods. Gene expression analysis by liver cells, 6 hepatoblastoma cell lines, and hepatoblastoma cells was performed. Immunohistochemistry was used to evaluate CD203c, CD326, and cytokeratin-19 expression on three hepatoblastoma tumors. Results: Antibody screening identified many cell surface markers commonly or divergently expressed by hematopoietic cells, LSECs, and hepatoblasts. Thirteen novel markers expressed on fetal hepatoblasts were identified including ectonucleotide pyrophosphatase/phosphodiesterase family member 3 (ENPP-3/CD203c), which was found to be expressed by hepatoblasts with widespread expression in the parenchyma of the fetal liver. In culture CD203c Conclusions: CD203c is expressed on hepatoblasts and may play a role in purinergic signaling in the developing liver. Hepatoblastoma cell lines were found to consist of two broad phenotypes consisting of a cholangiocyte-like phenotype that expressed CD203c and CD326 and a hepatocyte-like phenotype with diminished expression of these markers. CD203c was expressed by some hepatoblastoma tumors and may represent a marker of a less differentiated embryonal component.

Indexed as

antigensCD203cendothelial cellsfetal cellshepatoblastomahepatoblastshepatologyleukocytes

Identifiers

PMID36845728
PMCPMC9947649

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.